Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.73 |
| ▸ | CTSD | P07339 | 16/20 | 0.73 |
| ▸ | BACE2 | Q9Y5Z0 | 14/20 | 0.71 |
| ▸ | REN | P00797 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL5660837 | 0.94 | BACE1 (0.67) | BACE1CTSDBACE2REN | |
| SCHEMBL2795876 | 0.87 | BACE1 (0.79) | BACE1CTSDBACE2REN | |
| SCHEMBL4066824 | 0.85 | BACE1 (0.79) | BACE1CTSDBACE2REN | |
| SCHEMBL13953601 | 0.85 | BACE1 (0.79) | BACE1CTSDBACE2REN | |
| SCHEMBL13953600 | 0.85 | BACE1 (0.79) | BACE1CTSDBACE2REN | |
| SCHEMBL8230708 | 0.85 | BACE1 (0.74) | BACE1CTSDBACE2REN | |
| SCHEMBL4073994 | 0.84 | BACE1 (1.00) | BACE1CTSDBACE2REN | |
| SCHEMBL4066528 | 0.83 | BACE1 (0.81) | BACE1CTSDBACE2REN | |
| SCHEMBL4072880 | 0.83 | BACE1 (0.81) | BACE1CTSDBACE2REN | |
| SCHEMBL4065493 | 0.83 | BACE1 (0.81) | BACE1CTSDBACE2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007145570-A9 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| US-20070299087-A1 | New Compounds 319 | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | US | disclosed |
| US-20070299087-A1 | New Compounds 319 | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | US | disclosed |
| WO-2007145570-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299087-A1 | New Compounds 319 | PSEN2, PSEN1, MAPT | BACE1 4/4885CTSD 2006/4885BACE2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.